This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, S. E. Articles by Mignano, L. R. Search for Related Content PubMed PubMed Citation Articles by Cohen, S. E. Articles by Mignano, L. R.

Nalbuphine Is Better Than Naloxone for Treatment of Side Effects After Epidural Morphine

Department of Anesthesia, Stanford University School of Medicine, Stanford, California

This study compared naloxone and nalbuphine when administered for treatment of side effects after epidural morphine, 5 mg, given for postcesarean analgesia. Patients requesting treatment for pruritus or nausea randomly received, in a double-blind fashion, up to three intravenous doses of either naloxone 0.2 mg (group 1; n = 20) or nalbuphine 5 mg (group 2; n = 20). The incidence of vomiting, the severity of nausea and pruritus, and the degree of sedation and pain were assessed before and 30 min after each dose. The first dose of nalbuphine decreased the incidence of vomiting (P < 0.005) and the severity of nausea and pruritus (P < 0.01), whereas naloxone caused no significant changes. Sedation scores increased after nalbuphine (P < 0.05) and remained unchanged after naloxone, whereas pain scores increased after naloxone (P < 0.01) and were unchanged after nalbuphine. Eighteen patients in group 1 and 12 in group 2 received a second dose, and 8 and 4 patients, respectively, a third dose. Other than decreased pruritus after the second dose with both drugs, no further changes occurred. We conclude that nalbuphine is superior to naloxone for the treatment of side effects after epidural morphine. However, persistent symptoms may require supplemental therapy, as repeated doses proved less effective than the initial dose.

This article has been cited by other articles:

				M.-C. Ko and S. M. Husbands Effects of Atypical {kappa}-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 193 - 200. [Abstract] [Full Text] [PDF]

				Y.-C. Yeh, T.-F. Lin, F.-S. Lin, Y.-P. Wang, C.-J. Lin, and W.-Z. Sun Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain Br. J. Anaesth., October 1, 2008; 101(4): 542 - 548. [Abstract] [Full Text] [PDF]

				M. C. H. Ko, H. Lee, M. S. Song, K. Sobczyk-Kojiro, H. I. Mosberg, S. Kishioka, J. H. Woods, and N. N. Naughton Activation of kappa -Opioid Receptors Inhibits Pruritus Evoked by Subcutaneous or Intrathecal Administration of Morphine in Monkeys J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 173 - 179. [Abstract] [Full Text]

				R. Twycross, M.W. Greaves, H. Handwerker, E.A. Jones, S.E. Libretto, J.C. Szepietowski, and Z. Zylicz Itch: scratching more than the surface QJM, January 1, 2003; 96(1): 7 - 26. [Abstract] [Full Text] [PDF]

				B. Ben-David, P. J. DeMeo, C. Lucyk, and D. Solosko Minidose Lidocaine-Fentanyl Spinal Anesthesia in Ambulatory Surgery: Prophylactic Nalbuphine Versus Nalbuphine Plus Droperidol Anesth. Analg., December 1, 2002; 95(6): 1596 - 1600. [Abstract] [Full Text] [PDF]

				X. Culebras, G. Gaggero, J. Zatloukal, C. Kern, and R.-A. Marti Advantages of Intrathecal Nalbuphine, Compared with Intrathecal Morphine, After Cesarean Delivery: An Evaluation of Postoperative Analgesia and Adverse Effects Anesth. Analg., September 1, 2000; 91(3): 601 - 605. [Abstract] [Full Text] [PDF]